Biotechnology Analyst Biegler, along with Dr. Giancarlo Moscol, Associate Professor in the Department of Breast Medical Oncology at MD Anderson Cancer Center, discuss LLY‘s upcoming EMBER-3 data from LLY, its potential to reshape the standard-of-care, and key insights from looming readouts at San Antonio Breast Cancer Symposium (SABCS) on an Analyst/Industry conference call to be held on November 21 at 4 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly, Verge announce milestones in ALS collaboration
- Eli Lilly & Co Appoints Procter & Gamble CEO to Board
- Eli Lilly appoints Jon Moeller to board of directors
- Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss
- Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial